We chose the combination of anti-CTLA-4/PD-1 antibodies as the gold standard immunotherapy treatment based on positive results in clinical trials.47, 48, 49 B16/F10 melanoma cells are more sensitive to the cytotoxic effect of AS1411 with lower IC50 than 4T1 (Figure 1C), and therefore it is expected that its combination with SMG1 inhibition elicits a stronger antitumor response compared with the 4T1 model (Figure 5). The gene discussed is CTLA4; the disease is melanoma.